The rationale for the combination of ICIs and PARP-is is based on the evidence that HRD cancers have a higher tumor mutational burden (TMB), leading to elevated neo-antigen loads and causing an increased anti-tumor immune response [76]. The gene discussed is PARP1; the disease is neoplasm.